A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis

NCT ID: NCT01640548

Last Updated: 2016-11-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-interventional, retrospective, cross sectional chart review study will evaluate the management of rheumatoid arthritis patients with a biologic in monotherapy. Data from eligible patients will be collected from the patient's last visit on the prior rheumatoid arthritis treatment and from the most recent visit for the biological monotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/= 18 years of age
* Diagnosis of rheumatoid arthritis by a Rheumatologist
* Patient being prescribed with a biologic in monotherapy

Exclusion Criteria

* N/A
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abergavenny, , United Kingdom

Site Status

Basildon, , United Kingdom

Site Status

Basingstoke, , United Kingdom

Site Status

Belfast, , United Kingdom

Site Status

Blackburn, , United Kingdom

Site Status

Bournemouth, , United Kingdom

Site Status

Cambridge, , United Kingdom

Site Status

Cannock, , United Kingdom

Site Status

Dewsbury, , United Kingdom

Site Status

Dudley, , United Kingdom

Site Status

Durham, , United Kingdom

Site Status

Eastbourne, , United Kingdom

Site Status

Edinburgh, , United Kingdom

Site Status

Glasgow, , United Kingdom

Site Status

Greenock, , United Kingdom

Site Status

Harlow, , United Kingdom

Site Status

Inverness, , United Kingdom

Site Status

Kirkcaldy, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Portsmouth, , United Kingdom

Site Status

Sheffield, , United Kingdom

Site Status

Truro, , United Kingdom

Site Status

Warrington, , United Kingdom

Site Status

Westbury-on-Trym, Bristol, , United Kingdom

Site Status

Wigan, , United Kingdom

Site Status

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML28372

Identifier Type: -

Identifier Source: org_study_id